OCGN News and Press, Ocugen, Inc. From 01/15/26

2026-01-15 14:16:03 ET Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy January 15, 2026 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaD...

2026-01-15 08:45:59 ET More on Ocugen Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript Ocugen outlines plans for three BLA filings in next three years amid global gene therapy expansion...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. control There are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical trials to date MALVERN, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or...

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocuge...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene t...

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44 th Annual J....

2026-01-06 00:20:44 ET The last time I spoke about Ocugen ( OCGN ) it was with respect to a Seeking Alpha article entitled " Ocugen: Two Gene Therapy Data Readouts In 2024 to Drive Value ". With respect to this article, I primarily went over the development of its gene t...

2025-11-26 15:13:03 ET More on Markets The 'Real' Economy Is In Real Trouble Boomer Blues, Not Gen Z? SPYI Vs. SPY: The Case For Covered Calls In Two Charts Mixed signals as S&P 500’s December strength weakens in recent decade Sociét&#...

2025-11-05 16:22:15 ET More on Ocugen Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript Ocugen: A Retinal Disease Juggernaut In The Making Seeking Alpha’s Quant Rating on Ocugen Historical earnings data for Ocugen Financial information for O...

2025-11-05 16:21:11 ET Ocugen, Inc. (OCGN) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Ramesh Ramachandran - Chief Accounting...